Högskolan i Skövde

his.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • apa-cv
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The Therapeutic Potential of Psilocybin and 3,4-Methylenedioxymethamphetamine in the Treatment of Depression and Post-Traumatic Stress Disorder
University of Skövde, School of Bioscience.
2020 (English)Independent thesis Basic level (degree of Bachelor), 15 credits / 22,5 HE creditsStudent thesis
Abstract [en]

The psychedelic psilocybin and the entactogen 3,4-methylenedioxymethamphetamine (MDMA) are being scientifically studied again after a long hiatus, and especially for their potential in the treatment of psychiatric disorders. Their profound effect on cognitive, perceptual, and affective processes have led to several clinical studies during the last decade that have forced the reconsideration of the utility of these substances. The research includes clinical trials with psilocybin-assisted psychotherapy for depressive and anxiety symptoms, and MDMA-assisted psychotherapy for the treatment of post-traumatic stress disorder (PTSD). The results have shown a significant reduction in depressive and anxiety symptoms in psilocybin-assisted psychotherapy, and in PTSD symptoms in MDMA-assisted psychotherapy, with acceptable adverse effects. Moreover, the reductions in symptoms have been shown to be sustained several years later. Given the results indicate short- and long-term safety and efficacy, even for treatment resistant conditions, this suggest that these substances administered with psychotherapy are promising and deserve to be taken seriously as a therapeutic tool. The present thesis provides an overview of the latest clinical studies on the treatment of depression, anxiety, and PTSD with psilocybin and MDMA, respectively, as well as reviews the history, mechanisms of action, the therapeutic process used with psilocybin and MDMA, and any adverse physiological and psychological effects of both substances.

Place, publisher, year, edition, pages
2020. , p. 37
Keywords [en]
3, 4-methylenedioxymethamphetamine, MDMA, psilocybin, entactogen, psychedelic, psilocybin-assisted psychotherapy, MDMA-assisted psychotherapy
National Category
Neurosciences
Identifiers
URN: urn:nbn:se:his:diva-18729OAI: oai:DiVA.org:his-18729DiVA, id: diva2:1450276
Subject / course
Cognitive Neuroscience
Educational program
Cognitive Neuroscience - Applied Positive Psychology
Supervisors
Examiners
Available from: 2020-07-01 Created: 2020-07-01 Last updated: 2020-07-01Bibliographically approved

Open Access in DiVA

fulltext(501 kB)1558 downloads
File information
File name FULLTEXT01.pdfFile size 501 kBChecksum SHA-512
715158cb7349fd95f2e38dadade372fe221c389a20132404478cf69c2e60dd84e6644904a99aef1dd93e19c2dc8eab7aa1ca0bef5853894b26ab7da8a0427662
Type fulltextMimetype application/pdf

By organisation
School of Bioscience
Neurosciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 1558 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 4129 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • apa-cv
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf